Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.

Abstract

AIMS:

The aim of this pooled sub-analysis of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) and Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock (CULPRIT-SHOCK) trial was to compare the clinical outcome of patients with acute myocardial infarction complicated by cardiogenic shock treated either with clopidogrel or the newer, more potent ADP-receptor antagonists prasugrel or ticagrelor.

METHODS AND RESULTS:

For the current analysis the primary endpoint was 1-year mortality and the secondary safety endpoint was moderate or severe bleedings until hospital discharge with respect to three different ADP-receptor antagonists. 856 patients were eligible for analysis. Of these, 507 patients (59.2%) received clopidogrel, 178 patients (20.8%) prasugrel and 171 patients (20.0%) ticagrelor as acute antiplatelet therapy. The adjusted rate of mortality after 1-year did not differ significantly between prasugrel and clopidogrel (hazard ratio [HR]: 0.81, 95% confidence interval [CI] 0.60-1.09, padj = 0.17) or between ticagrelor and clopidogrel treated patients (HR: 0.86, 95% CI 0.65-1.15, padj = 0.31). In-hospital bleeding events were significantly less frequent in patients treated with ticagrelor vs. clopidogrel (HR: 0.37, 95% CI 0.20 -0.69, padj = 0.002) and not significantly different in patients treated with prasugrel vs. clopidogrel (HR: 0.73, 95% CI 0.43 -1.24, padj = 0.24).

CONCLUSION:

This pooled sub-analysis is the largest analysis on safety and efficacy of three oral ADP-receptor antagonists and shows that acute therapy with either clopidogrel, prasugrel or ticagrelor is no independent predictor of 1-year mortality. Treatment with ticagrelor seems independently associated with less in-hospital moderate and severe bleeding events compared to clopidogrel. This finding might be due to selection bias and should be interpreted with caution.

• Authors: Martin Orban, Jan Kleeberger, Taoufik Ouarrak, Anne Freund, Hans-Josef Feistritzer, Georg Fuernau, Tobias Geisler, Kurt Huber, Dariusz Dudek, Marko Noc, Gilles Montalescot, Alexander Neumer, Paul Haller, Peter Clemmensen, Uwe Zeymer, Steffen Desch, Steffen Massberg, Steffen Schneider, Holger Thiele, Jörg Hausleiter
• Journal: Clinical research in cardiology : official journal of the German Cardiac Society (Clin Res Cardiol) Vol. 110 Issue 9 Pg. 1493-1503 (Sep 2021) ISSN: 1861-0692 [Electronic] Germany
• PMID: 33999281 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: © 2021. The Author(s).

Chemical References

• Platelet Aggregation Inhibitors
• Clopidogrel
• Prasugrel Hydrochloride
• Ticagrelor

Topics

• Aged
• Aged, 80 and over
• Clopidogrel (administration & dosage, adverse effects)
• Female
• Follow-Up Studies
• Hemorrhage (chemically induced)
• Humans
• Intra-Aortic Balloon Pumping (methods)
• Male
• Middle Aged
• Myocardial Infarction (complications, mortality, therapy)
• Percutaneous Coronary Intervention
• Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
• Prasugrel Hydrochloride (administration & dosage, adverse effects)
• Prospective Studies
• Shock, Cardiogenic (mortality, therapy)
• Ticagrelor (administration & dosage, adverse effects)